A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

Sanz-Altamira, Pedro; Ferrante, Karen J.; Jenkins, Roger L.; Lewis, W. David; Huberman, Mark S.; Stuart, Keith

doi:10.1002/(sici)1097-0142(19980615)82:12<2321::aid-cncr4>3.0.co;2-v

Cited by 73 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies that have used chemotherapeutic agents, 5-FU, mitomycin C, methotrexate, etoposide, doxorubicin, or cisplatin, against biliary tract tumors, only 10%-20% revealed a partial response [43][44][45][46] . However, gemcitabine has shown remarkable biological activity against biliary tract cancers in some clinical studies.…”

Section: Discussionmentioning

confidence: 99%

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread

Kohya

Kono²,

Miyazaki

2010

WJG

View full text Add to dashboard Cite

AIM:To evaluate the adequacy of surgical treatment of T2 gallbladder carcinoma (GBCa) according to tumor spread in the subserosal layer. METHODS:A series of 84 patients with GBCa were treated at Saga University Hospital, Japan between April 1989 and October 2008. The tumor stage was graded according to the TNM staging for GBCa from the American Joint Committee on Cancer Manual 6th edition. Tumor staging revealed 30 patients with T2 tumors. T2 GBCa was divided into three groups histologically by the extent of tumor spread in the subserosal layer, using a score of ss minimum (ss min), ss medium (ss med) or ss massive (ss mas). RESULTS:For ss min GBCa, there was no positive pathological factor and patient survival was satisfactory with simple cholecystectomy, with or without extra-hepatic bile duct resection. For ss med GBCa, some pathological factors, h-inf (hepatic infiltration), ly (lymphatic invasion) and n (lymph node metastasis), were positive. For ss mas GBCa, there was a high incidence of positive pathological factors. The patient group with extra-hepatic bile duct resection with D2 lymph node dissection (BDR with D2) and those with S4a5 hepatectomy had significantly better survival rates. CONCLUSION:We suggest that radical surgery is not necessary for ss min GBCa, and partial hepatectomy and BDR are necessary for both ss med and ss mas GBCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread

Kohya

Kono²,

Miyazaki

2010

WJG

View full text Add to dashboard Cite

show abstract

“…Roayaie et al [91] performed chemo-radiation therapy for postoperative patients with positive resection margins or nodal invasion and did not find any difference in the actuarial disease-free survival between the patients with or without adjuvant chemo-radiation. Sanz-Altamira et al [92] used 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma and found that 21% of the patients had significant responses. Ando et al [93] treated an IHCC patient with postoperative recurrence of multiple liver metastases, and a complete response was noted 1 year after the patient underwent 4 courses of hepatic arterial infusion therapy via a subcutaneously implanted injection port and received cisplatin.…”

Section: Adjunctive Therapymentioning

confidence: 99%

Current status of intrahepatic cholangiocarcinoma

Yang¹,

Yan²

2008

WJG

View full text Add to dashboard Cite

Intrahepatic cholangiocarcinoma (ICC) is a rare primary liver cancer with a global increasing trend in recent years. Symptoms tend to be vague and insidious in development, often are diagnosed at an advanced stage when only palliative approaches can be used with a median survival rate of months. Comparing with HCC, ICC tends to spread to lymph nodes early, and is rarely limited to the regional lymph nodes, with a frequent postoperative recurrence. Surgery is the only choice of curative therapy for ICC, but recently no consensus has been established for operation. Thus, more data from multiple centers and more cases are needed. Generally speaking, current adjunctive therapy cannot clearly improve survival. Further research is needed to find more effective radio-and chemotherapeutic regimens.

show abstract

“…[6][7][8] The results of palliative chemotherapy and/or radiotherapy remain poor. [9][10][11][12] Chemotherapy and radiotherapy used in the treatment of a wide variety of malignancies induces apoptosis in responsive cells. Failure to initiate apoptosis is a major factor limiting the eYcacy of these treatments.…”

mentioning

confidence: 99%

The expression of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium

Okaro¹,

Deery²,

Hutchins³

et al. 2001

Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma

Cited by 73 publications

References 14 publications

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread

Rational therapeutic strategy for T2 gallbladder carcinoma based on tumor spread

Current status of intrahepatic cholangiocarcinoma

The expression of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium

Contact Info

Product

Resources

About